Dr. Atwa was first appointed Head of Research for the MENA region (June 7, 2024) and subsequently promoted to Global Head of Clinical Research (September 5, 2024), reflecting his instrumental role in developing SensoDetect's clinical pipeline. He has overseen the ASD clinical study at Princess Nourah bint Abdulrahman University Hospital/King Abdullah Bin Abdulaziz University Hospital (KAAUH) in Riyadh. The interim results in 2025 validated key aspects of the company's diagnostic methodology and AI performance, positioning SensoDetect for the next stage of regulatory approvals and commercialization.

"Dr. Atwa's relocation to Sweden is a strategic milestone. It brings our clinical leadership even closer to our innovation center and accelerates the pathway to clinical excellence and broader commercialization," said PA Hedin, CEO of SensoDetect. "His leadership has secured a strong clinical backbone and his permanent presence in Sweden will further enhance our ability to deliver value for patients, partners, and shareholders."

Dr. Atwa commented: "SensoDetect is at the forefront of transforming psychiatric care. By integrating clinical expertise, AI, and international partnerships, we are building a foundation for scalable, cost-effective solutions in mental health. I am proud to now be based in Sweden, working hand-in-hand with our R&D and corporate teams, while continuing to support our international clinical programs."